Ibrutinib (a tyrosine kinase inhibitor targeting Bruton) is a standard of treatment in haematology. According to retrospective data, atrial fibrillation and systemic hypertension are common ibrutinib-related advserse events. The investigators aim at prospectively establishing the incidence of thesedrug related advsere events through clinical monitoring and attempt at identifying populations at risk.
Study Type
OBSERVATIONAL
Enrollment
60
Assistance Publique Hôpitaux de Paris - Centre Université de Paris
Paris, France
RECRUITINGIncidence of cardiovascular events on ibrutinib
Evaluate the incidence of cardiotoxicity (composite endpoint) in a cohort of patients referred to a cardio-oncology before initiation of ibrutinib.
Time frame: 6 months
Incidence of supra-ventricular arrythmias
Number of patients with supra-ventricular arrythmias
Time frame: 6 months
Incidence of systemic hypertension
Number of patients with systemic hypertension
Time frame: 6 months
Incidence of arterial embolism
Number of patients with systemic hypertension
Time frame: 6 months
Incidence of hemorraghe
Number of patients with hemorraghe
Time frame: 6 months
Safety mesures
Compare advsere events in patients with supr-ventricular arrhythmias according to the continuation or discontinuation of ibrutinib
Time frame: 1 year
Anticoagulants
Correlation between anti thrombotic strategies and cardiovascular outcomes
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.